About Event
The 2nd ADC Payload Summit is your exclusive platform for exploring discovery, medicinal chemistry, and pre-clinical insights into the next generation of ADC Payloads. From optimized Tubulin and DNA Damaging agents to the latest TOPO I inhibitors, to exploring exciting new payload modes of action like molecular glues, RNA Poly II inhibitors, and STING agonists – we’ve got you covered.
This is your opportunity to hear in-depth presentations from leading ADC developers focussed on physiochemical structural modifications and novel discoveries in the ADC payload field with the likes of Heidelberg Pharma, Merck ADC, Ryvu Therapeutics, Eisai, and many more.
Attend to Benefit From:
Key Agenda Highlights:
Explore Underutilized Payload Mechanisms
Gain insights into emerging payloads, such as RNA II polymerase inhibitors, photosensitizers, and NMT inhibitors, with data from Heidelberg Pharma, Pacylex, and Northeastern University.
Accelerate Degrader ADC Development
Dive into case studies on preclinical DACs, focusing on payload optimization, and conjugation strategies, with presentations from Merck ADC, Prelude Therapeutics, and Lycia Therapeutics.
Leverage Strategic Insights into the ADC Patent Landscape
Learn how to maximize payload IP and take advantage of patent expirations to differentiate your ADC pipeline with exclusive guidance from Dan Shores, a partner at Rothwell Figg.
Expand Discovery Platforms for Scalable Candidate Identification
Evaluate cutting-edge innovations in payload screening and discovery with insights from Ryvu Therapeutics and Hexagon Bio enabling faster identification of promising candidates.
Advance Immunostimulatory Payload Strategies
Understand the latest data on STING and TLR agonist payloads, including structural insights and preclinical validation, with talks from Bolt Biotherapeutics and Eisai.
Who Will Be There?
